Related Experiment Video
Updated: Apr 21, 2026

An Efficient Sieving Method to Isolate Intact Glomeruli from Adult Rat Kidney
Published on: November 1, 2018
Update on C3 glomerulopathy
Thomas D Barbour1, Marieta M Ruseva1, Matthew C Pickering1
1Centre for Complement and Inflammation Research (CCIR), Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London W12 0NN, UK.
Insights
C3 glomerulopathy involves abnormal complement system control, leading to kidney damage. Recent research clarifies its causes, focusing on complement factor H-related proteins and potential new treatments.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- C3 glomerulopathy is characterized by excessive C3 fragment deposition in the glomerulus, causing kidney damage.
- The primary issue is dysregulated complement activation, specifically uncontrolled C3b amplification.
- Abnormal complement factor H-related (CFHR) proteins are implicated in some cases, potentially by disrupting complement factor H (CFH) regulation.
Purpose of the Study:
- To summarize recent advancements in understanding C3 glomerulopathy pathogenesis.
- To highlight updated case definitions and diagnostic recommendations.
- To review emerging therapeutic strategies for C3 glomerulopathy.
Main Methods:
- Review of recent clinicopathological cohort studies.
- Analysis of family studies investigating CFHR protein abnormalities.
- Synthesis of published clinical experiences with complement-targeted therapies.
Main Results:
- Uncontrolled C3b amplification is identified as a key pathogenic mechanism.
- Structurally abnormal CFHR proteins are linked to C3 glomerulopathy through 'CFH de-regulation'.
- A 2013 consensus report refined case definitions and treatment guidelines.
Conclusions:
- Understanding of C3 glomerulopathy pathogenesis has significantly improved.
- Targeted therapies, including C5 inhibitors, show early clinical promise.
- Continued research is crucial for refining diagnosis and treatment of this rare kidney disease.
Abstract:
C3 glomerulopathy refers to a disease process in which abnormal control of complement activation, degradation or deposition results in predominant C3 fragment deposition within the glomerulus and glomerular damage. Recent studies have improved our understanding of its pathogenesis. The key abnormality is uncontrolled C3b amplification in the circulation and/or along the glomerular basement membrane. Family studies in which disease segregates with structurally abnormal complement factor H-related (CFHR) proteins demonstrate that abnormal CFHR proteins are important in some types of C3 glomerulopathy. This is currently thought to be due to the ability of these proteins to antagonize the major negative regulator of C3 activation, complement factor H (CFH), a process termed 'CFH de-regulation'. Recent clinicopathological cohort studies have led to further refinements in case definition, culminating in a 2013 consensus report, which provides recommendations regarding investigation and treatment. Early clinical experience with complement-targeted therapeutics, notably C5 inhibitors, has also now been published. Here, we summarize the latest developments in C3 glomerulopathy.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Nephrotic Syndrome I : Introduction
Diabetic Nephropathy
Nephrotic Syndrome III : Nursing Management
Cytomegalovirus Disease

